124 related articles for article (PubMed ID: 31067347)
21. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.
Prorok PC; Andriole GL; Bresalier RS; Buys SS; Chia D; Crawford ED; Fogel R; Gelmann EP; Gilbert F; Hasson MA; Hayes RB; Johnson CC; Mandel JS; Oberman A; O'Brien B; Oken MM; Rafla S; Reding D; Rutt W; Weissfeld JL; Yokochi L; Gohagan JK;
Control Clin Trials; 2000 Dec; 21(6 Suppl):273S-309S. PubMed ID: 11189684
[TBL] [Abstract][Full Text] [Related]
22. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
23. Screening for prostate cancer: the current evidence and guidelines controversy.
Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
[TBL] [Abstract][Full Text] [Related]
24. Other and All-Cause Mortality among Men Diagnosed with Prostate Cancer in the PLCO Trial.
Pierre-Victor D; Pinsky PF; Miller E; Parnes H
J Urol; 2021 May; 205(5):1372-1378. PubMed ID: 33350321
[TBL] [Abstract][Full Text] [Related]
25. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of a Negative Prostate Biopsy: An Analysis of Subjects Enrolled in a Prostate Cancer Screening Trial.
Lewicki P; Shoag J; Golombos DM; Oromendia C; Ballman KV; Halpern JA; Stone BV; O'Malley P; Barbieri CE; Scherr DS
J Urol; 2017 Apr; 197(4):1014-1019. PubMed ID: 27836710
[TBL] [Abstract][Full Text] [Related]
27. Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel.
Kim EH; Andriole GL; Crawford ED; Sjoberg DD; Assel M; Vickers AJ; Lilja H
J Urol; 2017 Apr; 197(4):1041-1047. PubMed ID: 27810449
[TBL] [Abstract][Full Text] [Related]
28. Vasectomy and Risk of Prostate Cancer in a Screening Trial.
Shoag J; Savenkov O; Christos PJ; Mittal S; Halpern JA; Askin G; Shoag D; Golan R; Lee DJ; O'Malley P; Najari B; Eisner B; Hu JC; Scherr D; Schlegel P; Barbieri CE
Cancer Epidemiol Biomarkers Prev; 2017 Nov; 26(11):1653-1659. PubMed ID: 28830873
[No Abstract] [Full Text] [Related]
29. Evidence of a healthy volunteer effect in the prostate, lung, colorectal, and ovarian cancer screening trial.
Pinsky PF; Miller A; Kramer BS; Church T; Reding D; Prorok P; Gelmann E; Schoen RE; Buys S; Hayes RB; Berg CD
Am J Epidemiol; 2007 Apr; 165(8):874-81. PubMed ID: 17244633
[TBL] [Abstract][Full Text] [Related]
30. Past, Current, and Future Incidence Rates and Burden of Metastatic Prostate Cancer in the United States.
Kelly SP; Anderson WF; Rosenberg PS; Cook MB
Eur Urol Focus; 2018 Jan; 4(1):121-127. PubMed ID: 29162421
[TBL] [Abstract][Full Text] [Related]
31. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
Pinsky PF; Crawford ED; Kramer BS; Andriole GL; Gelmann EP; Grubb R; Greenlee R; Gohagan JK
BJU Int; 2007 Apr; 99(4):775-9. PubMed ID: 17223921
[TBL] [Abstract][Full Text] [Related]
32. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial.
Grubb RL; Pinsky PF; Greenlee RT; Izmirlian G; Miller AB; Hickey TP; Riley TL; Mabie JE; Levin DL; Chia D; Kramer BS; Reding DJ; Church TR; Yokochi LA; Kvale PA; Weissfeld JL; Urban DA; Buys SS; Gelmann EP; Ragard LR; Crawford ED; Prorok PC; Gohagan JK; Berg CD; Andriole GL
BJU Int; 2008 Dec; 102(11):1524-30. PubMed ID: 19035857
[TBL] [Abstract][Full Text] [Related]
33. Obesity and prostate cancer screening, incidence, and mortality in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
Hurwitz LM; Dogbe N; Barry KH; Koutros S; Berndt SI
J Natl Cancer Inst; 2023 Dec; 115(12):1506-1514. PubMed ID: 37382561
[TBL] [Abstract][Full Text] [Related]
34. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
35. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciatto S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
J Med Screen; 2013 Mar; 20(1):33-38. PubMed ID: 28075228
[TBL] [Abstract][Full Text] [Related]
36. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
[TBL] [Abstract][Full Text] [Related]
37. A System Dynamics Model of Serum Prostate-Specific Antigen Screening for Prostate Cancer.
Palma A; Lounsbury DW; Schlecht NF; Agalliu I
Am J Epidemiol; 2016 Feb; 183(3):227-36. PubMed ID: 26702631
[TBL] [Abstract][Full Text] [Related]
38. Update of the results of the Spanish branch of the European Randomized Study on Screening for Prostate Cancer (ERSPC).
Luján M; Páez Á; Angulo JC; Andrés G; Gimbernat H; Redondo C; Torres GM; Berenguer A
Actas Urol Esp; 2015 Sep; 39(7):405-13. PubMed ID: 25777669
[TBL] [Abstract][Full Text] [Related]
39. Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence.
Hayes JH; Barry MJ
JAMA; 2014 Mar; 311(11):1143-9. PubMed ID: 24643604
[TBL] [Abstract][Full Text] [Related]
40. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
